Open Label Continuation Study in Moderate to Severe Psoriasis

This study has been completed.

Sponsor:

AbbVie (prior sponsor, Abbott)

ClinicalTrials.gov Identifier:

NCT00626002

First Posted: February 29, 2008

Last Update Posted: January 30, 2013

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Having participated in a preceding ABT-874 clinical trial for ABT-874

Subject has a clinical diagnosis of moderate to severe plaque psoriasis

Exclusion Criteria:

Subjects who prematurely discontinued in any preceding psoriasis study with ABT-874 other than protocol-required discontinuation

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00626002